CTRI/2023/09/058050
Active, not recruiting
Phase 2
A Randomized Placebo Control Study To Evaluate The Efficacy Of Individualized Homoeopathic Medicines In Cases Of Haemorrhoids - NI
Jawaharlal Nehru Homoeopathic Medical College & Hospital0 sites0 target enrollmentTBD
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Health Condition 1: K649- Unspecified hemorrhoids
- Sponsor
- Jawaharlal Nehru Homoeopathic Medical College & Hospital
- Status
- Active, not recruiting
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Pre\-diagnosed cases, New diagnosed cases .
- •2\. Following cases were included irrespective of their sex, caste, religion.
- •3\. Patient of age group 18 \- 60 years (both gender) from all socioeconomic status.
- •4\. Diagnosed cases of Haemorrhoids who have taken medicines from any other system of treatment like Allopathy, Ayurvedic, etc, were also be considered after a washout period of 15 days.
- •5\. Patients who have taken previously Homoeopathy medicines prior to the visit were also taken into consideration after 1 month of washout period.
- •6\. The patients who have given their consent to participate in study with follow ups.
Exclusion Criteria
- •1\. The cases which did not fulfil the inclusion criteria.
- •2\. Patient having Haemorrhoids in association with other autoimmune disorders.
- •3\. Cases with other advanced pathology.
- •4\. 4th Degree Prolapse of Rectum.
- •5\. Pregnant women and lactating mothers.
- •6\. Patients not giving written consent.
- •7\. Cases with irregular follow up
Outcomes
Primary Outcomes
Not specified
Similar Trials
Not yet recruiting
Phase 2
A study to evaluate the effect of AYUSH SR as adjunct to usual care for cardiac rehabilitation on biochemical, physical and psychological parameters, in adult patients who underwent Coronary Artery Bypass Graft (CABG) surgeryHealth Condition 1: I251- Atherosclerotic heart disease of native coronary arteryCTRI/2023/09/057564Central Council for Research in Ayurvedic Science (CCRAS) Ministry of AYUSH, Government of India
Active, not recruiting
Not Applicable
Safety and efficacy of tocilizumab in combination with placebo compared with tocilizumab in combination with methotrexate, with possible addition of other disease-modifying antirheumatic drugs (DMARDs), in patients with moderate to severe active rheumatoid arthritis who are not responding adequately to their current therapy with methotrexateEUCTR2008-001847-20-LVF Hoffmann-La Roche Ltd.470
Active, not recruiting
Not Applicable
Safety and efficacy of tocilizumab in combination with placebo compared with tocilizumab in combination with methotrexate, with possible addition of other disease-modifying antirheumatic drugs (DMARDs), in patients with moderate to severe active rheumatoid arthritis who are not responding adequately to their current therapy with methotrexateRheumatoid ArthritisMedDRA version: 14.1Level: PTClassification code 10039073Term: Rheumatoid arthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersTherapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]EUCTR2008-001847-20-SEF Hoffmann-La Roche Ltd.470
Active, not recruiting
Not Applicable
Safety and efficacy of tocilizumab in combination with placebo compared with tocilizumab in combination with methotrexate, with possible addition of other disease-modifying antirheumatic drugs (DMARDs), in patients with moderate to severe active rheumatoid arthritis who are not responding adequately to their current therapy with methotrexateRheumatoid ArthritisMedDRA version: 14.0Level: PTClassification code 10039073Term: Rheumatoid arthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersTherapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]EUCTR2008-001847-20-DEF Hoffmann-La Roche Ltd.470
Active, not recruiting
Not Applicable
Safety and efficacy of tocilizumab in combination with placebo compared with tocilizumab in combination with methotrexate, with possible addition of other disease-modifying antirheumatic drugs (DMARDs), in patients with moderate to severe active rheumatoid arthritis who are not responding adequately to their current therapy with methotrexateRheumatoid ArthritisMedDRA version: 14.1Level: PTClassification code 10039073Term: Rheumatoid arthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersTherapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]EUCTR2008-001847-20-DKF Hoffmann-La Roche Ltd.470